Navigation Links
Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
Date:9/3/2009

CRANBURY, N.J., Sept. 3 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced that it will present at the Rodman & Renshaw 11(th) Annual Global Investment Conference on Wednesday, September 9, 2009 at 4:55 PM ET. The conference is being held at the New York Palace Hotel, New York, NY.

Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies, will provide an update on Palatin's corporate and development programs. A live audio broadcast will be available on the "Investors" section of Palatin's website at www.palatin.com. The live audio broadcast will be available through September 22, 2009.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
2. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
3. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
4. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Receives Notification Letter from NYSE Alternext US
7. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
8. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
9. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
10. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
11. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... global consumption of squalene / squalane is expected to be ... that finds applications in various end user industries such as ... applications like high grade lubrication, and fiber coating additives. ... is regionally segregated. Sophim ( France ), Amyris ... Japan ), SeaDragon Marine Oils Ltd. ( New ...
(Date:9/17/2014)... 2014 Shimadzu Scientific Instruments ... (2D-LC), which offers a powerful separation method ... system provides a new level of knowledge ... beneficial to scientists analyzing pharmaceutical impurities, proteins, ... , Comprehensive 2D-LC combines two independent separation ...
(Date:9/17/2014)... 2014 BioClinica®, Inc., a leading provider of ... three of its experts are speaking at the ... to be held September 28 to October 1 in ... also announced the innovative Compass technology, a ... trials acquired earlier this year, is up for the ...
(Date:9/17/2014)... -- Hussey Copper , a leader in copper ... announces Gilmour Academy Ice Arena,s conversion of more than ... touch surface to help protect against bacteria.  MD-Cu 29 ... kills greater than 99.9% of MRSA, E-coli and other ... , Innovative Gilmour Academy prepares ...
Breaking Biology Technology:Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3
... , , , ... NGSX ), a biopharmaceutical company focused on developing and commercializing ... Goodwin to its Board of Directors as a director and Audit ... President and CEO of Keren Pharmaceutical, a company focused on exploiting ...
... , , , WALTHAM, ... leading research and advisory firms for pharmaceutical and healthcare issues, ... most notably Novartis,s Diovan -- the hypertension drug market will ... the market will decrease by 1.4 percent annually and thereafter ...
... , GAITHERSBURG, Md., Aug. 25 GenVec, Inc. (Nasdaq: ... Phase 2 Small Business Innovation and Research (SBIR) grant from the ... Institutes of Health (NIH) to support the development of GenVec,s vector ... http://www.newscom.com/cgi-bin/prnh/ 2 0081205/DC50112LOGO ) , , ...
Cached Biology Technology:NeurogesX Appoints New Board Director and Audit Committee Chairman 2NeurogesX Appoints New Board Director and Audit Committee Chairman 3NeurogesX Appoints New Board Director and Audit Committee Chairman 4NeurogesX Appoints New Board Director and Audit Committee Chairman 5Hypertension Drug Market Will Experience Only Modest Annual Decline Through 2018, Despite Generic Erosion Of Many Branded Agents 2GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development 2
(Date:9/17/2014)... September 17, 2014 Researchers at UTSouthwestern Medical ... the circulating protein apolipoprotein E, called apoE3, helps repair ... called apoE4, do not get the benefit of this ... , "We believe that we have identified one mechanism ... why a genetic variant, apoE4, is detrimental," said ...
(Date:9/17/2014)... 1960s. The typical development phases of trees and stands ... as much as 70 percent. This was the outcome ... Universitt Mnchen based on long-term data from experimental forest ... findings were published recently in Nature Communications . ... topic, with the very survival of large forest ecosystems ...
(Date:9/17/2014)... including MRSA and MSSA could be curbed by ... the scaly surface of shark skin, according to ... Antimicrobial Resistance and Infection Control . , The ... spread of human disease bacteria through touching, sneezes ... arrangement of ridges formulated to resemble shark skin. ...
Breaking Biology News(10 mins):Protein variant may boost cardiovascular risk by hindering blood vessel repair 2Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3Sharks' skin has teeth in the fight against hospital superbugs 2
... real cost of Herceptin is borne by other patients whose ... doctors in this week’s BMJ. , New guidance from the ... (Herceptin) in early breast cancer, but it provides no extra ... to release this extra money. This leaves medical staff with ...
... larvae, warmed in a toasty lab chamber, are giving Cornell ... see how genes are expressed in living tissue. , Using ... Watt W. Webb, researchers have for the first time been ... activate their genes to synthesize key proteins in fruit fly ...
... protein converts chemical energy to mechanical force, thus powering ... structural model by University of North Carolina at Chapel ... a scientific mystery: how the protein dynein fuels itself ... include mitosis, or cell division into identical cells. ...
Cached Biology News:Other patients bear the real cost of Herceptin 2Researchers use multiphoton microscopy to watch chromosomes in action 2Researchers use multiphoton microscopy to watch chromosomes in action 3UNC scientists solve mystery of how largest cellular motor protein powers movement 2
Template and primers for preparation of internal control spots...
Biotin-OSu is used to label proteins, immunological agents, DNA and synthetic oligonucleotides. Biotin labeling is detected through enzymatically labeled avidin or streptavidin proteins that conforma...
EGTA, 10 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
GOAT ANTI FRK...
Biology Products: